Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
December 2011, Vol 2, No 7
December 2011, Vol 2, No 7
FDA Revokes Bevacizumab’s Breast Cancer Indication
FDA Approvals, News & Updates
December 2011, Vol 2, No 7
The FDA has revoked its previous accelerated (and conditional) approval for bevacizumab (Avastin, Genentech) for the treatment of metastatic breast cancer (MBC), citing safety concerns that outweigh its benefits in this patient population.
Read Article
5-Year Analysis of VISTA Confirms Survival Advantage with Bortezomib for Patients with Myeloma
By
Audrey Andrews
ASH 2013 Annual Meeting
December 2011, Vol 2, No 7
Patients with multiple myeloma receiving bortezomib (Velcade) in the pivotal VISTA trial lived more than 1 year longer than those in the control group, according to the final, 5-year analysis of the study presented at the 2011American Society of Hematology annual meeting.
Read Article
Dual HER2 Blockade with Pertuzumab Substantially Delays Disease Progression
By
Caroline Helwick
CTRC-AACR SABCS Annual Meeting
December 2011, Vol 2, No 7
San Antonio, TX—It is becoming increasingly clear that 2 agents are better than 1 in treating HER2-positive advanced breast cancer.
Read Article
GPCI, or “GYPSY”: Calculated or Covert Cuts to Oncology Reimbursement
By
Robert Gamble
Health Policy
,
Policies & Guidelines
December 2011, Vol 2, No 7
Read Article
Frontier Cancer Care in Montana on the Leading Edge of Patient Care
Best Practices
,
Policies & Guidelines
December 2011, Vol 2, No 7
Interview with Patrick Cobb, MD, FACP
Read Article
Economic Implications of Biosimilars in Oncology
By
Caroline Helwick
Drug Updates
,
Biosimilars
December 2011, Vol 2, No 7
Alternative versions of biologic agents—biosimilars—will be coming soon to a formulary near you. In the meantime, many details must be worked out before patients can be safely and effectively treated with these new products.
Read Article
“Pediatric-Inspired” Regimens Improve Outcomes in Adults with ALL
By
Phoebe Starr
NCCN Conference
December 2011, Vol 2, No 7
Adults with acute lymphoblastic leukemia (ALL) have a poor prognosis compared with children, but recent studies suggest that using “pediatric-inspired” regimens can improve outcomes for patients with Philadelphia chromosome(Ph)- negative ALL.
Read Article
A New Paradigm of Value-Based Cancer Care: The NCCCP
By
Mark J. Krasna, MD
Cancer Care
,
Economics & Value
,
Value-Based Care
December 2011, Vol 2, No 7
Read Article
Ruxolitinib a New Oral Option for the Treatment of Patients with Intermediate- or High-Risk Myelofibrosis Disorders
By
Rhonda Williams
Cancer Drugs
,
Personalized Medicine
December 2011, Vol 2, No 7
Myeloproliferative neoplasms (MPNs) are a group of closely related hematologic malignancies that arise from abnormal development and function of the body’s bone marrow cells. Primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET) comprise the Philadel phia chromosome (Ph)-negative MPNs.
Read Article
Pathologists Can Play Key Role in the Era of Personalized Oncology
By
Rosemary Frei, MSc
American Pathologists Meeting
December 2011, Vol 2, No 7
The role of pathologists in gathering and interpreting oncologic information has never been as complex as it is today, but neither has it been as clinically impactful, suggested presenters at the 2011 College of American Pathologists meeting.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma